CMTS0929
Phase 1Biologic
CMTS0929 is one of 57 biologic programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Inflammatory Bowel Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Dificlir
Merck & Co.Approved
Calciferol
Jazz PharmaceuticalsApproved
Mounjaro
Eli LillyApproved
Elavil
AstraZenecaApproved
Avandia
Jazz PharmaceuticalsApproved
Zyloprim
Jazz PharmaceuticalsApproved
Aplenzin
GGlaxo Dba Glaxosmithkline
Approved
Spravato
WWim Janssens
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Clostridioides difficile Infection1 trial
CMTS0929 for Clostridioides Difficile Infection
Not yet recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06836427·12 enrolled
Inflammatory Bowel Disease1 trial
CMTS0929 for Inflammatory Bowel Disease
Not yet recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06844708·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CMTS0929. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details